{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:28:58Z","timestamp":1782152938524,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CSCO-Hengrui Research Foundation","award":["No. Y-HR2018-143, Y-HR2018-144"],"award-info":[{"award-number":["No. Y-HR2018-143, Y-HR2018-144"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04550-9","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:14:11Z","timestamp":1766024051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuanzhuan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"4550_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4550_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"issue":"5","key":"4550_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","volume":"2","author":"M Schlumberger","year":"2014","unstructured":"Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356\u20138.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"4550_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35(8):841\u2013985.","journal-title":"Thyroid"},{"key":"4550_CR5","doi-asserted-by":"crossref","unstructured":"Lebbink CA, Links TP, Czarniecka A, Dias RP, Elisei R, Izatt L, et al. 2022 European Thyroid Association guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022;11(6):e220146.","DOI":"10.1530\/ETJ-22-0146"},{"issue":"4","key":"4550_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"RM Tuttle","year":"2019","unstructured":"Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461\u201370.","journal-title":"Thyroid"},{"issue":"8","key":"4550_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9940","key":"4550_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328.","journal-title":"Lancet"},{"issue":"7","key":"4550_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330.","journal-title":"N Engl J Med"},{"issue":"9","key":"4550_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825\u201335.","journal-title":"N Engl J Med"},{"issue":"6","key":"4550_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186(6):631\u201343.","journal-title":"Eur J Endocrinol"},{"key":"4550_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101013","volume":"72","author":"H Shen","year":"2024","unstructured":"Shen H, Zhu R, Liu Y, Hong Y, Ge J, Xuan J, et al. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resist Updat. 2024;72:101013.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"4550_CR13","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(8):1126\u201338.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4550_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","volume":"17","author":"M Schlumberger","year":"2021","unstructured":"Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17(3):176\u201388.","journal-title":"Nat Rev Endocrinol"},{"key":"4550_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20163934","author":"G Varricchi","year":"2019","unstructured":"Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20163934.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4550_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","volume":"19","author":"JM Mehnert","year":"2019","unstructured":"Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 2019;19(1):196.","journal-title":"BMC Cancer"},{"issue":"8","key":"4550_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.34657","volume":"129","author":"DY Oh","year":"2023","unstructured":"Oh DY, Algazi A, Capdevila J, Longo F, Miller W Jr., Chun Bing JT, et al. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer. 2023;129(8):1195\u2013204.","journal-title":"Cancer"},{"issue":"1","key":"4550_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"5","key":"4550_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"4550_CR20","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"14","key":"4550_CR21","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u2013300.","journal-title":"N Engl J Med"},{"issue":"7","key":"4550_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31(7):1076\u201385.","journal-title":"Thyroid"},{"issue":"17","key":"4550_CR23","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","volume":"30","author":"JD French","year":"2024","unstructured":"French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, et al. Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin Cancer Res. 2024;30(17):3757\u201367.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4550_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","volume":"8","author":"Y Lin","year":"2022","unstructured":"Lin Y, Qin S, Li Z, Yang H, Fu W, Li S, et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial. JAMA Oncol. 2022;8(2):242\u201350.","journal-title":"JAMA Oncol"},{"issue":"8","key":"4550_CR25","doi-asserted-by":"publisher","first-page":"e3027","DOI":"10.1210\/clinem\/dgab196","volume":"106","author":"YS Lin","year":"2021","unstructured":"Lin YS, Zhang X, Wang C, Liu YQ, Guan WM, Liang J. Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer. J Clin Endocrinol Metab. 2021;106(8):e3027\u201336.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"4550_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ. Camrelizumab: first global approval. Drugs. 2019;79(12):1355\u201361.","journal-title":"Drugs"},{"issue":"18","key":"4550_CR27","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","volume":"333","author":"YL Liang","year":"2025","unstructured":"Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, et al. Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial. JAMA. 2025;333(18):1589\u201398.","journal-title":"JAMA"},{"issue":"9","key":"4550_CR28","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024;30(9):2549\u201357.","journal-title":"Nat Med"},{"issue":"10408","key":"4550_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"key":"4550_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943916","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Zhang X, Mu Z, Sun D, Sun Y, Lin Y. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: a case report and literature review. Front Immunol. 2022;13:943916.","journal-title":"Front Immunol"},{"key":"4550_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.712107","volume":"12","author":"P Adam","year":"2021","unstructured":"Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Knosel T, et al. FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale. Front Endocrinol (Lausanne). 2021;12:712107.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"4550_CR32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1210\/clinem\/dgae512","volume":"110","author":"B Konda","year":"2025","unstructured":"Konda B, Sherman EJ, Massarelli E, Nieva J, Muzaffar J, Morris JC 3rd, et al. Cabozantinib plus ipilimumab\/nivolumab in patients with previously treated advanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2025;110(3):830\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"4550_CR33","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1158\/1078-0432.CCR-22-3613","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, et al. Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2023;29(15):2791\u20139.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"4550_CR34","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1200\/JCO.22.01450","volume":"41","author":"X Ding","year":"2023","unstructured":"Ding X, Zhang WJ, You R, Zou X, Wang ZQ, Ouyang YF, et al. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study. J Clin Oncol. 2023;41(14):2571\u201382.","journal-title":"J Clin Oncol"},{"issue":"34","key":"4550_CR35","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.20.01920","volume":"38","author":"C Lan","year":"2020","unstructured":"Lan C, Shen J, Wang Y, Li J, Liu Z, He M, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2020;38(34):4095\u2013106.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4550_CR36","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/S1470-2045(21)00460-5","volume":"22","author":"H Cheng","year":"2021","unstructured":"Cheng H, Zong L, Kong Y, Wang X, Gu Y, Cang W, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2021;22(11):1609\u201317.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4550_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","volume":"46","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019;46(1):57\u201364.","journal-title":"Semin Oncol"},{"key":"4550_CR38","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhang X, Lin L, Xing M. Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab. 2025;110(3):873\u2013886.","DOI":"10.1210\/clinem\/dgae617"},{"issue":"20","key":"4550_CR39","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1158\/1078-0432.CCR-21-0761","volume":"27","author":"X Zheng","year":"2021","unstructured":"Zheng X, Xu Z, Ji Q, Ge M, Shi F, Qin J, et al. A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2021;27(20):5502\u20139.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04550-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:31:40Z","timestamp":1769121100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04550-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4550"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04550-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted with the approval of the Hospital Ethics Committee of Peking Union Medical College Hospital (No. JS-2071) and in accordance with the principles of the Declaration of Helsinki (as revised in 2013). All patients involved in the study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}